Subject has provided informed consent prior to initiation of any study specific activities/procedures.; Age = 18 years at signing of informed consent.; Subject has a diagnosis of Atopic Dermatitis (according to American Academy of Dermatology Consensus Criteria) that has been present for at least 6 months before signing of informed consent.;

Prior to informed consent, history of inadequate response to TCS of medium or higher potency within 6 months (with or without TCI as appropriate).;

Active malignancy, multiple myeloma, myeloproliferative or lymphoproliferative disorder, or a history of any of these conditions within 5 years prior to informed consent (except curatively treated in situ cervical carcinoma, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma).; History of major immunologic reaction (eg, serum sickness, anaphylaxis, or anaphylactic reaction) to any other biologic product or any excipient of rocatinlimab.; Diagnosis of a helminth parasitic infection within 6 months prior to day 1 prerandomization that had not been treated with or had failed to respond to standard of care therapy.; Evidence of human immunodeficiency virus (HIV) infection or positive for HIV antibodies at initial screening or current acquired, common variable or inhibited, primary or secondary immunodeficiency.;

Positive for hepatitis C virus (HCV) antibody at initial screening with confirmed positive HCV RNA.;

• Atopic Dermatitis

• Dermatology

• Internal Medicine

• Amgen